ArticleFrontiers in oncology2026
Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pre-TACE CK-MB/CK Ratio as an Independent Prognostic Biomarker in Advanced Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aim to develop a nomogram that can effectively differentiate target hepatocellular carcinoma (HCC) patients to receive immunotherapy and categorize their risk levels. Methods: This retrospective study analyzed 328 patients with HCC who had received anti-programmed cell death-1 (PD-1) drugs between January 2019 and December 2022. Univariate and multivariate Cox regression analyses were used to identify potential prognostic factors. The novel nomograms were then established based on the above independent predictors and assessed by Harrell's concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curve analyses (DCA). Kaplan-Meier curves were performed to estimate the progression-free survival (PFS) and overall survival (OS) based on risk scores. Results: Survival analyses identified the treatment sequence, disease progression with bone or lymph node, and Child-Pugh classification as prognostic factors for PFS and Barcelona Clinic Liver Cancer (BCLC) stage, Child-Pugh stage, ascites, Eastern Cooperative Oncology Group Performance Status (ECOG PS), surgery, disease progression with lymph node, and neutrophil-to-lymphocyte ratio (NLR) for OS. The PFS model had a C-index of 0.657 (0.609-0.705), matching validation set performance [0.657 (0.582-0.733)]. OS model C-indices were 0.787 (0.748-0.826) and 0.671 (0.606-0.736) for training and validation cohorts. Calibration plots and DCA curves indicated high accuracy and applicability. Significant differences in OS and PFS times were observed between low- and high-risk groups based on current nomogram points ( Conclusions: The prognostic nomogram based on patients' demographics and clinicopathological factors showed reliable efficacy in predicting survival benefits in intermediate and advanced-stage HCC patients following immunotherapy, aiding in individual decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.